Major results of the three trials with factor Xa inhibitors versus warfarin (data are n/N)
| Aristotle | Rocket-AF | Engage AF | |||||
|---|---|---|---|---|---|---|---|
| Apixaban | Warfarin | Rivaroxaban | Warfarin | Edoxaban 60 mg | Edoxaban 30 mg | Warfarin | |
| Primary end point | 212/9120* | 265/9081 | 269/7081 | 306/7090 | 296/7035 | 383/7034 | 337/7036 |
| Mortality | 603/9120* | 669/9081 | 208/7061 | 250/7082 | 773/7035 | 737/7034* | 839/7036 |
| Ischaemic stroke | 149/9120 | 155/9081 | 149/7061 | 161/7082 | 236/7035 | 333/7034* | 235/7036 |
| Haemorrhagic stroke | 40/9120* | 78/9081 | 29/7061* | 50/7082 | 49/7035* | 30/7034* | 90/7036 |
| Myocardial infarction | 90/9120 | 102/9081 | 101/7061 | 126/7082 | 133/7035 | 169/7034 | 141/7036 |
| Major bleeding | 327/9088* | 462/9052 | 395/7111 | 386/7125 | 418/7012* | 254/7002* | 524/7012 |
| Gastrointestinal bleeeding | 105/9088 | 119/9052 | 224/7111* | 154/7125 | 232/7012* | 129/7002* | 190/7012 |
*Labelled as significantly different versus warfarin in the original report.